UK drug update - May 2004

Published: 1-May-2004
Regulatory


Alpharma has brought out 25mg tablets of the cytotoxic immunosuppressant azathioprine. The company has also made available 30mg tablets of the 5HT reuptake inhibitor paroxetine, and Vascalpha 5mg and 10mg tablets of the class II calcium antagonist felodipine.

Actelion Pharmaceuticals has launched Zavesca containing 100mg of the glucosylceramide synthase inhibitor miglustat.

Sandoz has added the following products to its range: 100mg and 200mg tablets of the folic acid inhibitor trimethoprim; and 500/125mg tablets and 125/31.25mg and 250/62.5mg per 5mL oral suspension of the beta-lactamase inhibitor/broad spectrum penicillin combination product co-amoxiclav (amoxicillin with clavulanic acid).

IVAX Pharmaceuticals has launched 5mg and 10mg tablets of the class II calcium antagonist amlodipine.

Novartis has brought out Glivec tablets. The film-coated tablets contain 400mg of the Bcr-Abl tyrosine kinase inhibitor imatinib.

Celltech has marketed a 30mg/mL injection of the class III antiarrhythmic agent amidarone hydrochloride in a Minijet prefilled syringe.

Roche has introduced Bondronat tablets. The 50mg tablets contain the biphosphonate ibandronic acid. The company has also made available its recombinant human erythropoietin product NeoRecormon (epoetin beta) in a 30,000 international units per prefilled syringe presentation.

Bristol-Myers Squibb has launched Reyataz capsules. The product contains 100mg, 150mg or 200mg of the protease inhibitor atazanavir (equivalent to 113.9mg, 170.8mg or 227.8mg of atazanavir sulfate).

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now